manibiotech,
We didn’t know for sure that this is what might need to be done but MHRA and NWBO both did. Therefore, cooperation was in play. As I have said consistently, manufacturing had to be in place to rapidly move to closed and automated after any approval of artisan then point of care needed to be considered as the goal after that. This is all preparation for changes in manufacturing processes by regulators and companies advancing new tech. Gee, I wonder if NWBO could be one of the companies spearheading this change with MHRA which is why MHRA can say there is no more backlog?; ). Best wishes.
Market Data 
Markets 
AI
